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Introduction: Distinguishing synchronous primary lung cancers
(SPLCs) from advanced disease is important because prognosis and
treatments are very different and a surgical approach to SPLC may
result in survival similar to solitary cancers. Determining this dis-
tinction with certainty, however, is challenging. We reviewed our
experience with surgical resection of presumed SPLC to analyze
outcomes and identify factors associated with prolonged survival.
Patients and Methods: A retrospective review identified patients
treated for presumptive SPLC. Cases were defined using modified
criteria set forth by Martini and Melamed and histologic subtyping.
Survival was estimated using the Kaplan-Meier method, and factors
associated with survival were evaluated using a log-rank test or Cox
proportional hazards model for categorical and continuous variables,
respectively.
Results: From January 1995 to July 2006, 175 patients met study
criteria and underwent complete resection. Tumors were more often
in different lobes of an ipsilateral chest (55 of 175, 31%) or
contralateral lesions (45 of 175, 26%). More than half (104 of 175,
59%) of the patients underwent a single operation. Median fol-
low-up was 50.3 months (4.8–164.7); median overall survival (OS)
for the group was 67.4 months (46.4–80.0) with a 3-year OS of
64%. On multivariable analysis controlling for stage, only female
gender was a significant predictor of better OS (p  0.001).
Conclusions: An aggressive surgical approach to patients with
apparent SPLC can result in survival that is comparable with
patients with single lung cancers of similar stage. The Martini
and Melamed criteria and histologic subtyping can identify ap-
propriate patients for resection. Female gender was associated
with superior OS.
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The distinction of synchronous primary lung cancers(SPLC) from primary lung cancer with pulmonary metas-
tasis is important because the prognosis and treatments are
markedly different. The outcome achieved by medical treat-
ment alone for an additional lesion of the same histology in
the ipsilateral chest (T4 or M1 in the current staging system)
is poor.1 Nevertheless, the diagnosis of SPLC presents a
clinical dilemma because there are no rigorous clinical or
histopathological criteria by which such a distinction can be
made.2,3 Therefore, it is not surprising that estimates of the
incidence of SPLC vary, with published rates ranging be-
tween 0.2% and 20% of all patients with non-small cell lung
cancer.4,5 The most commonly used criteria to define syn-
chronous or metachronous malignant lung disease were pro-
posed by Martini and Melamed6 more than 30 years ago.
These guidelines suggest that for lesions of similar histology,
in the absence of extrathoracic metastases and lymphatic
metastases in the common drainage basins, it is reasonable to
treat patients for second primary disease. These criteria were
based mainly on metachronous lesions, because only 18 of
the patients in that study had SPLC but have proven to be
durable and provide the basis for the American College of
Chest Physicians lung cancer clinical practice guidelines
from 2007.7 In addition, a number of recent, small case series
have supported the role of resection of SPLC as defined by
these criteria.1,8–10 Nakata et al.1 reported 3-year survival
rates of 77.9% in 26 patients with synchronous SPLC, and a
larger series has shown that the 5-year survival of patients
with SPLC without lymph node metastasis exceeds 50%.11,12
Often, patients who have tumors meeting SPLC criteria are
considered to have more advanced disease and are not offered
surgical resection, which negatively impacts their overall
survival (OS).
The goal of this study was to review our institutional
experience with primary surgical resection for patients with
presumed SPLC to identify factors associated with prolonged
survival and to identify additional criteria, which may be
useful to distinguish patients with SPLC from those with
more advanced disease.
PATIENTS AND METHODS
Identification of Patients and Inclusion Criteria
Approval for the study was obtained, and the need for
individual patient consent was waived by the institutional
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review/privacy board. An institutional review board-ap-
proved prospectively maintained database of all thoracic
surgical patients undergoing lung cancer resection at a single
institution was used to identify patients undergoing surgical
resection of SPLC, defined as two or more cancers with the
following clinical and pathologic criteria modified from Mar-
tini and Melamed6:
1. Presence of tumors with different histologies (e.g., ad-
enocarcinoma versus squamous cell carcinoma).
2. Tumors of different histologic subtypes:(e.g., different
estimated percentages of acinar versus bronchoalveolar
versus papillary adenocarcinoma), regardless of nodal
status.
3. Tumors of similar histology but arising from separate
foci (e.g., in the case of squamous cell carcinoma, the
presence of in situ carcinoma in both tumors).
4. Tumors of similar histology in the absence of metastatic
disease in intervening regional or mediastinal lymph
node stations and the absence of extrathoracic disease.
All patients identified had a complete chart review and
were included in the study only if they met the above criteria.
If there was a question of whether a patient met SPLC
criteria, the case was reviewed by two surgeons (D.J.F. and
B.J.P.) and two pathologists (W.T. and A.Y.), and the original
surgeon was contacted, if possible. Patients previously treated
for single primary lung cancers who subsequently presented
with metachronous, multiple tumors were excluded from the
study. Patients with bronchioalveolar carcinoma as the only
histology in all lesions were not included. Patients with SPLC
who subsequently developed metachronous lung cancers
were included. The final pathologic stage assigned each
patient was that of the most advanced staged lesion resected.
A formal pathologic review was performed on all available
tumors by two of the authors (A.Y. and W.T.) using the 2004
World Health Organization classification including a recently
proposed modification of adenocarcinoma subtyping pro-
posed by Motoi et al.13 Patients who did not have specimens
available for review were excluded. Patients with tumors
other than non-small cell carcinoma were excluded.
The treatment paradigm used for SPLC diagnosed pre-
operatively is shown in Figure 1. Extent of disease evaluation
varied depending on the treating surgeon but typically in-
FIGURE 1. This preoperative treatment paradigm helps in determining whether patients, who are found to have more than
one pulmonary nodule on computed tomography (CT) scan of the chest, have synchronous primary lung cancer (SPLC) ver-
sus metastatic disease. Positron emission tomography (PET)/CT and mediastinoscopy are useful tools but are never 100% ac-
curate. Preservation of pulmonary parenchyma is paramount.
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cluded a computed tomography chest and upper abdomen,
bone scan, and brain imaging. When available, whole body
positron emission tomography became standard and re-
placed bone scan in the majority of cases. In cases of
suspected SPLC, cervical mediastinoscopy was routinely
performed to rule out nodal metastases, and more recently,
endobronchial ultrasound with transbronchial needle aspi-
ration has been used. In cases where there was a clinical
suspicion for nodal disease but the endobronchial ultra-
sound-transbronchial needle aspiration was benign, medi-
astinoscopy was performed. Surgical resection was per-
formed by means of an open or a video assisted thoracic
surgery technique at the discretion of the operating sur-
geon. Systematic nodal dissection was performed in all the
patients. Data on patient demographics, treatment, and
survival were extracted from the surgical database and
from the electronic medical record. All complications were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0
(http://ctep.cancer.gov/reporting/ctc.html).
Statistical Methodology
Survival was calculated from the date of first surgery to
either date of death or the last follow-up date, including all
in-hospital mortalities. The date of death was obtained from
either the institutional medical record or Social Security
Death Index. OS rate was estimated using the Kaplan-Meier
method. Variables potentially affecting survival were ana-
lyzed including gender, age, smoking history, time of diag-
nosis (preoperatively versus intraoperatively), tumor location
(same lobe, ipsilateral different lobe, or contralateral lung),
histology (same versus different), and pathologic stage of the
more advanced lesion. Factors significantly associated with
survival were identified by using the log-rank test for cate-
gorical variables or Cox proportional hazard regression anal-
ysis for continuous variables. The Cox proportional hazard
regression method was used to report hazard ratios. The
stratified log-rank test was used to calculate p values for the
categorical variables after controlling for stage. All analyses
were performed using statistical packages Statistical Analysis
Software 9.1 or R 2.3.1. All p values are two sided. A p value
of less than 0.05 was considered statistically significant.
RESULTS
Patient Demographics
From January 1995 to July 2006, a total 428 patients
were identified as having more than one lung tumor resected.
One hundred seventy-five patients had metachronous disease.
Sixty-eight patients were excluded because they had either a
single cancer or evidence supporting stage IV disease (ex-
trathoracic metastatic lesions). Ten patients with suspected
SPLC had insufficient specimens for pathologic review. This
left 175 patients meeting study criteria who underwent com-
plete resection of SPLC and had complete clinical and patho-
logic data available. The median age was 69 years (range
42–87), and 62% of the patients were female. Most were
former or current smokers (92%) with a median cigarette
exposure of 45 pack-years (range 0–216). Only 14 patients
were never smokers. Roughly half of the patients (n  91,
52%) were diagnosed preoperatively as having SPLC,
whereas 42% (73 of 175) had additional lesions discovered at
the time of operation for a single lesion. Only nine patients
had their lesions detected as part of a computed tomography
Screening Program. Eleven patients (6%) had suspected
SPLC preoperatively and were found to have additional
lesions identified at exploration for a known lesion.
Treatment
More than half (102 of 175, 58%) of the patients
underwent a single operation, whereas 73 patients (42%)
underwent two or more operations (Table 1). In all cases,
complete resection was performed while maintaining optimal
lung parenchymal preservation. The majority of patients (148
of 175, 84%), regardless of whether they underwent single or
multiple operations, had either a single lobectomy (100 of
175, 57%) and/or sublobar resections (48 of 175, 27%). Ten
patients underwent sequential bilateral lobectomies, and 13
patients required bilobectomy. Pneumonectomy was rarely
performed (5 of 175, 3%). Operative morbidity was 33%, the
majority of which was grade 1 or 2 (91 of 99 complications),
and in-hospital mortality was 1.2%. Most patients received no
additional therapy after complete resection. Twenty-five pa-
tients (14%) received adjuvant therapy with 17 undergoing
chemotherapy and eight having external beam radiotherapy.
Tumor Characteristics and Stage
The median size of the largest resected tumor was 2.5
cm (range 0.5–14) (Table 2). Most patients (125 of 175, 71%)
had two tumors; however, 29% (50 of 175) had more than
two tumors, with one patient having a total of 11. Multiple
TABLE 1. Operative Details
No. of operations (%), n  175
One 104 (59)
Two or more 71 (41)
Extent of resection for a single operation (%), n  102
Sublobar resection 32 (31)
Wedge resection 20 (19)
Segmentectomy 12 (12)
Lobectomy 59 (58)
Bilobectomy 8 (8)
Pneumonectomy 3 (3)
Extent of resection for multiple operations (%), n  73
Sublobar resections 16 (22)
Multiple wedge resections 5 (7)
Multiple segmentectomies 4 (5)
Segmentectomy  wedge resection 7 (10)
Lobectomy  sublobar resection 41 (56)
Lobectomy  segmentectomy 12 (16)
Lobectomy  wedge resection 29 (40)
Bilateral lobectomies 10 (14)
Bilobectomy  sublobar resection 4 (5)
Pneumonectomy  sublobar resection 2 (3)
Over half of the patients had a single operation, and a lobectomy was performed the
majority of the time. Extensive resections, including bilobectomy and pneumonectomy,
were performed on only 17 patients.
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adenocarcinomas comprised the majority (76%) of cases.
There were relatively few cases of different histologies (34 of
175, 19%). After detailed histologic subtyping, only seven
tumors were considered the same. None of these patients had
lymph node metastasis. The most common tumor locations
were in different lobes of an ipsilateral chest (55 of 175, 31%)
followed by contralateral lesions (45 of 175, 26%). Overall,
ipsilateral disease was slightly more common that contralat-
eral disease (59% versus 41%). The majority of patients had
node-negative, stage I disease, but 25 patients (14%) had N1
disease, and 22 patients (13%) had N2 disease.
Survival
The median follow-up was 50.3 months (4.8–164.7);
the median OS for the group was 67.4 months (46.4–80.0)
with a 3-year OS of 64% (Figure 2). In the cohort of patients
with only two lesions (n  125), the median survival was
54.8 months (34.8–80) with a 3-year OS of 59.5% (95%
confidence interval: 50.0–67.7%; data not shown). Univari-
ate analysis of factors associated with survival revealed that
decreasing size of the largest tumor, fewer pack-years of
cigarettes smoked, female gender, and T-, N-, and overall
pathologic stage were associated with improved survival
(Table 3). Tumor location, tumor histology, and time of
diagnosis (preoperative versus intraoperative) did not seem to
influence survival. There was no pattern to recurrence, re-
gardless of the type of resection the patients underwent (data
not shown). Patients with stage IA disease had a significantly
better OS than patients with higher stage disease (p  0.001)
(Figure 3). Patients with stages IB, II, and III disease did not
have statistically significantly different survival, although
there was a trend toward worse survival. Survival was similar
regardless of the location of the additional disease (Figure 4).
On multivariable analysis controlling for stage, only female
gender was a significant predictor of better OS (p  0.001).
DISCUSSION
Since first described in 1924 by Beyreuther,14 SPLC
were considered to be associated with a poor prognosis.
Subsequent studies of SPLC (Table 4) have been difficult to
interpret due to small overall numbers of cases and little
information regarding tumor characteristics and stage. In
addition, there are wide differences in surgical technique and
FIGURE 2. The 3-year overall survival (OS)
was 64% for all patients. In the cohort of
patients with only two lesions, the 3-year
OS was 59.5% (p  nonsignificant [NS]).
TABLE 2. Tumor Characteristics
Median no. of lesions (range) 2.5 (2–11)
Median size largest lesion, cm (range) 2.5 (0.5–14)
Histology (%)
Multiple adenocarcinomas 133 (76)
Multiple squamous cell carcinomas 8 (5)
Adenocarcinoma and squamous cell carcinoma 13 (7)
Adenocarcinoma and othera 17 (10)
Squamous cell carcinoma and othera 2 (1)
Multiple othersa 2 (1)
Tumor location (%)
Same lobe 27 (15)
Ipsilateral, different lobe 55 (31)
Contralateral 45 (26)
Same lobe  ipsilateral lobe 23 (13)
Same lobe  contralateral lobe 17 (10)
Ipsilateral lobe  contralateral lobe 8 (5)
Highest stage, n (%)
IA 78 (44)
IB 49 (28)
IIA 12 (7)
IIB 15 (9)
IIIA 21 (12)
Adenocarcinomas comprised the majority of the tumors. Ipsilateral disease was
more common than contralateral disease, with ipsilateral-different lobe being the most
common presentation of SPLC in this series. Patients presented with stages IA and IB
in 72% of cases.
a Other histologies include large cell carcinoma, adenosquamous, pleomorphic
carcinoma, and large cell neuroendocrine carcinoma.
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no standard with respect to adjuvant treatment, all of which
compound the difficulties in evaluating this data. The initial
report from our institution by Martini and Melamed6 and the
follow-up study by Rosengart et al.,15 which documented
pathologic stage, allowed for more accurate evaluation of the
outcome of patients treated for SPLC. The OS of patients
with SPLC in these two studies, although slightly worse than
patients with single primary lung cancer, was clearly better
than for patients with stage IIIB or IV disease.6,15
In this study, we report the largest series to date of
surgically treated SPLCs. We have demonstrated that with
the careful use of clinical and histopathological criteria,
thorough staging and appropriate surgical intervention OS
rates comparable with patients with single lung cancers of
similar stage can be achieved. Patients in this study with
stages IA and IB SPLC who were surgically treated had a
74% and 65% 3-year OS, respectively. This is similar to
patients with single lung cancers, when matched for stage16
and highlights the need to distinguish patients with SPLC
from those with more advanced disease. The results presented
here are consistent with other modern, albeit smaller, series of
surgically treated SPLC.1,17
In attempting to identify factors associated with pro-
longed survival, univariate analysis revealed that decreasing
tumor size, fewer pack-years of cigarettes smoked, female
sex, T-, N-, and overall pathologic stage were associated with
TABLE 3. Univariate Analysis of Predictors of Survival
Variable Name N 3 yr OS Rate% (95% CI) Hazard Ratio (95% CI) p
Overall 175 64.0 (56–71)
Continuous variables
Cigarette pack/yr 170 1.01 (1.00–1.01) 0.021a
Largest tumor size (cm) 175 1.11 (1.01–1.23) 0.033a
Total no. of tumor 175 0.83 (0.64–1.07) 0.149a
Categorical variables
Gender 0.001
Female 108 77.0 (68–84) Ref. level
Male 67 41.2 (29–53) 2.21 (1.45–3.38)
Cigarette Hx (one missing) 0.457
Current 19 50.5 (26–71) Ref. level
Former 141 65.6 (57–73) 0.86 (0.46–1.64)
Never 14 71.4 (41–88) 0.54 (0.2–1.47)
Preoperative vs. intraoperative 0.948
Preoperative 91 64.8 (54–74) Ref. level
Intraoperative 73 63.6 (51–74) 0.95 (0.61–1.47)
Pre  intra 11 60.6 (26–83) 1.07 (0.46–2.52)
Tumor location 0.6
Same lobe 27 68.3 (46–83) Ref. level
Ipsilateral 78 59.5 (47–70) 1.4 (0.73–2.7)
Contralateral 70 66.7 (54–77) 1.31 (0.68–2.51)
Histology 0.054
Same 146 66.8 (58–74) Ref. level
Different 29 50.3 (31–67) 1.64 (0.99–2.74)
Largest T stageb 0.001
1 97 72.7 (62–81) Ref. level
1 78 53.1 (41–64) 1.99 (1.3–3.04)
Highest N levelb 0.012
0 128 69.1 (60–77) Ref. level
1 25 48.6 (27–67) 1.96 (1.11–3.47)
2 22 50.5 (27–70) 1.96 (1.08–3.53)
Highest stageb 0.001
IA 78 74.0 (62–83) Ref. level
IB 49 65.0 (50–77) 1.64 (0.97–2.76)
II 27 44.3 (25–63) 2.72 (1.49–4.96)
III 21 47.8 (25–68) 2.85 (1.46–5.54)
Three year OS was 64%, with a median OS of 67.4 mo for the group. Smoking history, tumor location, and time of diagnosis did not
seem to influence survival. Stage, increasing size of largest tumor, gender, and similar histology were associated with improved survival.
a p values are obtained based on or the score test based on the Cox proportional hazards model.
b The largest tumor, the most distant nodal disease, and highest stage were calculated based on the most extensive tumor in each patient.
OS, overall survival; CI, confidence interval.
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improved survival. On multivariate analysis controlling for
stage, only female gender was an independent predictor of
survival. This is consistent with multiple series of both single
and multiple primary lung cancers.6,8,11,12,15,16,18–20 Chang et
al.11 recently reported similar results, finding that nodal status
was a significant prognostic factor. The OS was lower than in
this report, which may be due to the selection criteria that
included all patients with a second tumor at the time of
resection, regardless of lymph node status or location, poten-
tially including a significant number of patients with stage
IIIB or stage IV disease.
Trousse et al.12 recently reported their data on 125
consecutive patients with SPLC over a 20-year period. In this
study, patients with tumor spread to common lymphatic
channels were included, raising the concern that these pa-
tients in fact had advanced disease. This concern is supported
by the fact that 40% of the patients in their study had adjuvant
treatment, and the reported 5-year survival was only 34%. In
this study, a central pathologic review was performed, and
patients who had positive nodal disease were excluded if
there tumors were felt to be identical on histologic subtyping.
This reduced the inclusion of patients with true stage IIIB or
stage IV disease.
Nearly one half of the patients in our study had syn-
chronous disease recognized intraoperatively, and 60% of
patients had ipsilateral disease. Survival outcomes of surgical
resection were similar regardless of the location of the addi-
tional primary disease (same lobe, ipsilateral, or contralateral)
and were better than expected under the current staging
system. This supports the changes to the T-stage descriptor
FIGURE 3. Patients with stage IA disease
had 3-year overall survival (OS) of 74%,
which was statistically better than patients
with higher stage disease.
FIGURE 4. There was no difference in
overall survival (OS), regardless of tumor
location.
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proposed by the International Association for the Study of
Lung Cancer.21,22 They report a median 5-year OS for pa-
tients with M1 disease (same side tumors and different lobes),
which was similar to patients with T4 disease (p  0.109).
They also found that patients with T4 tumors (same lobe and
multiple tumors) had similar 5-year OS to patients with T3
tumors (p  0.6488).22 Generally, when an additional lesion
is found at the time of surgery, we will proceed with the
planned resection if the patient meets our modified SPLC
criteria. That is, if there is no pleural disease, the intervening
lymph node stations are negative on frozen section, and the
new nodules do not appear to have been spread through the
pleura, we will proceed with complete resection. Our data
support these results and our intraoperative SPLC criteria.
These data also demonstrated excellent survival results for
contralateral tumors that far exceed what would be expected
for M1 disease in the contralateral lung.
Adenocarcinomas often comprised various histologic
subtypes (acinar, papillary, etc.),23 suggesting that these tu-
mors have different origins. Given that most patients in this
study had tumors of the same histology (81%) of which 76%
were adenocarcinomas, distinguishing patients who were
truly SPLC based on overall histologic type (i.e., adenocar-
cinoma) was not possible. Unfortunately, strict adherence to
the Martini and Melamed criteria can misidentify patients as
having SPLC when in fact they have metastatic disease.24
However, by defining the percentage contribution of each
subtype for individual tumors allowed for the differentiation
of tumors which were potentially SPLC from those that were
metastatic lesions.13 The validity of this method is suggested
by the improved survival of these patients, even those with
lymph node metastasis, when compared with what would be
expected historically of patients with stages IIIB and IV
disease. In an effort to explore these findings, we recently
completed a molecular analysis of suspected SPLC tumors.
These results confirmed the validity of histologic subtyping in
helping to identify patients with SPLC.25
There are several potential limitations of this study.
First, because of the retrospective nature of this study, the
results are based on a highly selected group of patients in
which there are probably inherent biases. Second, as the
incidence of this entity is low, it was difficult to make
conclusions about certain subgroups, such as higher stage
patients (II and III) or to distinguish outcomes achieved in
patients with similar or different histologies. The low num-
bers within these subgroups may explain the fact that we did
not see a statistical difference in survival between patients
with stage II and stage III disease. Third, we cannot know the
outcome of patients who had SPLC but were never offered
surgical resection, thus not allowing us to compare patients
surgically treated to those medically treated. Finally, we have
not discovered additional helpful criteria in distinguishing
SPLC from more advanced disease.
There have been 14 studies that propose using molec-
ular characterization to aid in distinguishing synchronous
tumors from metastatic lesions,26–39 the majority of which did
not use any specific inclusion criteria to select tumors. Ad-
ditionally, most used loss of heterozygosity or p53 mutational
analysis, both of which are often not able to distinguish
between these two distinct clinical entities. Others proposed
TABLE 4. Summary of the Major Studies Reporting on Synchronous Primary Lung Cancers Over the Last 30 yr
Authors References Year n
Histology (%) Location (%) Survival
Similar Different Unilateral Bilateral Median (mo) 3 yr (%) 5 yr (%)
Martini and Melamed 6 1975 18 72 18 78 22 24 37 28
Mathisen 40 1984 10 NR NR 0 100 14 10 0
Ferguson et al. 9 1985 28 68 32 39 61 NR NR NR
Wu 43 1987 10 50 50 90 10 29 48 35
Deschamps 44 1990 36 33 67 65 14 14 28 16
Rosengart et al. 15 1991 33 48 52 76 24 38 55 44
Verhagen 45 1994 15 80 20 67 33 20 26 15
Ribet and Dambron 10 1995 24 58 42 37 63 15 18 0
Angeletti 46 1995 18 33 67 56 44 48 63 46
Antakil 47 1995 26 NR NR 46 56 15 12 12
Adebonojo et al. 4 1997 15 80 20 67 33 43 58 0
Okada et al. 8 1998 28 43 57 75 25 60 95 70
Van Rens et al. 20 2000 73 59 41 49 51 24 37 20
Rea 48 2001 19 68 32 47 53 33 52 20
Vansteenkiste 49 2001 35 86 14 80 20 28 48 33
Aziz 50 2002 10 70 30 60 40 31 40 10
Nakata et al. 1 2004 26 100 0 35 65 60 92 NR
Tsunezuka et al. 17 2004 19 50 50 0 100 90 82 69
Chang et al. 11 2007 92 88 12 88 12 36 50 35
Trousse et al. 12 2007 125 83 17 27 73 35 48 34
Riquet 51 2008 118 51 49 92 8 26 40 26
NR, not reported.
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the use of epidermal growth factor receptor and kirsten rat
sarcoma mutational analysis, but these are not ubiquitous
enough to be used in this patient population. Initial work by
both Bhattacharjee et al.40 and Garber et al.41 suggest that it
is feasible to differentiate tumors based on molecular profil-
ing. Combining the clinical and pathologic paradigm outlined
earlier with molecular profiling may help provide a more
accurate diagnosis of SPLC in the future.7
This large series shows that using modified criteria
originally set forth by Martini and Melamed, based on current
precise histologic subtyping and rigorous mediastinal and
extrathoracic staging, we can identify patients with probable
SPLC who will benefit from curative resection (Figure 1).
Evolving methods in molecular profiling of these lesions may
further improve our ability to definitively characterize this
challenging entity.
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